Overview

  • Product nameAnti-CD45 antibody [104-2]
    See all CD45 primary antibodies
  • Description
    Mouse monoclonal [104-2] to CD45
  • Tested applicationsSuitable for: Flow Cyt, ICC/IF, IPmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    The details of the immunogen for this antibody are not available.

  • General notes

    ab25052 recognizes CD45 (Leukocyte Common Antigen) on all leukocytes of mouse strains expressing the CD45.2 allotype (e.g. A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). It is useful as a marker for origin of donor and host cells

Properties

Applications

Our Abpromise guarantee covers the use of ab25052 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use at an assay dependent concentration. ab170191-Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
ICC/IF Use at an assay dependent concentration.
IP Use at an assay dependent concentration.

Target

  • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
  • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
  • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.
  • DomainThe first PTPase domain interacts with SKAP1.
  • Post-translational
    modifications
    Heavily N- and O-glycosylated.
  • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
  • Information by UniProt
  • Database links
  • Alternative names
    • B220 antibody
    • CD 45 antibody
    • CD45 antibody
    • CD45 antigen antibody
    • CD45R antibody
    • GP180 antibody
    • L-CA antibody
    • LCA antibody
    • Leukocyte common antigen antibody
    • loc antibody
    • Ly-5 antibody
    • LY5 antibody
    • Ly5, homolog of antibody
    • Lyt-4 antibody
    • OTTHUMP00000033813 antibody
    • OTTHUMP00000033816 antibody
    • OTTHUMP00000033817 antibody
    • OTTHUMP00000038574 antibody
    • Protein tyrosine phosphatase receptor type c polypeptide antibody
    • protein tyrosine phosphatase, receptor type, C antibody
    • Ptprc antibody
    • PTPRC_HUMAN antibody
    • Receptor-type tyrosine-protein phosphatase C antibody
    • T200 antibody
    • T200 glycoprotein antibody
    • T200 leukocyte common antigen antibody
    see all

Anti-CD45 antibody [104-2] images

  • Analysis of C57BL/6 mouse splenocyte necrosis after exposure to Trypanosoma evansi trypanosomes in the presence or absence of anti-CD45 antibodies. Splenocyte necrosis was blocked with ab25052 at 15 µg/5.105 cells.

    C: Mock-exposed splenocytes
    T: Splenocytes exposed to the trypanosomes after preconditioning with PBS
    T CD45.1: Splenocytes exposed to the trypanosomes after preconditioning with ab25078
    T CD45.2: Splenocytes exposed to the trypanosomes after preconditioning with ab25052

References for Anti-CD45 antibody [104-2] (ab25052)

This product has been referenced in:
  • Antoine-Moussiaux N  et al. A non-cytosolic protein of Trypanosoma evansi induces CD45-dependent lymphocyte death. PLoS One 4:e5728 (2009). Inhibition Assay ; Mouse . Read more (PubMed: 19478957) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab25052.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"